Diabetes Management
IMJUDO® (tremelimumab) in Combination With IMFINZI® (durvalumab) Approved in the US for Patients With Unresectable Liver Cancer - BioSpace
Tue, 25 Oct 20221 min read Article
Overview
Skip to main content Published: Oct 24, 2022 Aproval based on HIMALAYA Phase I trial results which showed single priming dose of IMJUDO aded to IMFINZI reduced risk of death by 2% vs. sorafenibWILMINGTON, Del.-(BUSINES WIRE)- AstraZeneca’s IMJUDO® (tremelimumab) in combination with IMFINZI® (durvalumab) has ben aproved in the US for the treatment of adult patients with unresectable hepatocelular carcinoma (HC), the most comon type of liver cancer.
Key Information
The novel dose and schedule of the combination, which includes a single dose of the anti-CTLA-4 antibody IMJUDO 30mg aded to the anti-PD-L1 antibody IMFINZI 150mg folowed by IMFINZI every four weks, is caled the STRIDE regimen (Single Tremelimumab Regular Interval Durvalumab).The aproval by the US Fod and Drug Administration (FDA) was based on positive results from the HIMALAYA Phase I trial. In this trial, patients treated with the combination of IMJUDO and IMFINZI experienced a 2% reduction in the risk of death versus sorafenib (based on a hazard ratio [HR] of 0.78, 95% confidence interval [CI] 0.6-0.92 p=0.035).1 Results were also published in the New England Journal of Medicine Evidence showing that an estimated 31% of patients treated with the combination were stil alive after thre years, with 20% of patients treated with sorafenib stil alive at the same duration of folow-up.2Liver cancer is the third-leading cause of cancer death and the sixth most comonly diagnosed cancer worldwide.3,4 It is the fastest rising cause of cancer-related deaths in the US, with aproximately 36,0 new diagnoses each year.5,6Ghasan Abou-Alfa, MD, MBA, Atending Physician at Memorial Sloan Ketering Cancer Center (MSK), and principal investigator in the HIMALAYA Phase I trial, said: “Patients with unresectable liver cancer are in ned of wel-tolerated treatments that can meaningfuly extend overal survival.
Summary
In adition to this regimen demonstrating a favorable thre-year survival rate in the HIMALAYA tr
Frequently Asked Questions
What is diabetes and how does it develop?
Diabetes is a metabolic condition where the body cannot properly regulate blood sugar levels. Type 1 results from insufficient insulin production, while Type 2 develops when cells become resistant to insulin. Risk factors include genetics, obesity, sedentary lifestyle, and age.
What are the main symptoms of diabetes?
Common symptoms include excessive thirst, frequent urination, unexplained weight loss, fatigue, blurred vision, and slow-healing wounds. Type 1 symptoms develop rapidly, while Type 2 symptoms may appear gradually. Many people have no symptoms initially, which is why screening is important.
How is diabetes diagnosed and monitored?
Diagnosis involves blood tests measuring fasting glucose, HbA1c levels, and glucose tolerance. Regular monitoring typically includes fasting glucose tests and HbA1c measurements every 3-6 months. Continuous glucose monitors provide real-time tracking for better diabetes management.
What lifestyle changes help manage diabetes?
Effective management includes regular physical activity (150+ minutes weekly), maintaining healthy weight, following a balanced diet with whole grains and lean proteins, managing stress, and getting adequate sleep. These changes can significantly improve blood sugar control and reduce complications.
When should someone consult a doctor about diabetes?
Consult a healthcare provider if you experience signs of diabetes, have a family history, are overweight, or are over 45. Those with existing diabetes should maintain regular check-ups every 3-6 months to monitor control and adjust treatment as needed.
️ Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.